Table 2.

Adverse events in ≥2 patients

	SAD Stage		MD Stage
No. (%) Patients	Placebo (n = 6)	All Active (n = 24)	Placebo (n = 7)	1.5 mg/kg (SC) (n = 12)	3.5 mg/kg (SC) (n = 12)	5.0 mg/kg (IV)(n = 5)	All Active(n = 29)
Adverse Events
Any event	1 (17)	6 (25)	0 (0)	1 (8)	3 (25)	1 (20)	5 (17)
Nausea	0 (0)	2 (8)	0 (0)	0 (0)	1 (8)	0 (0)	1 (3)
Flank pain	0 (0)	2 (8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Fatigue	0 (0)	0 (0)	0 (0)	1 (8)	1 (8)	0 (0)	2 (7)
Pruritis	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	1 (20)	2 (7)
Rash	0 (0)	0 (0)	0 (0)	0 (0)	1 (8)	1 (20)	2 (7)
Serious Adverse Events
Any event	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

IV, intravenous; MD, multiple dose; SAD, single ascending dose; SC, subcutaneous.

*Adverse events determined by investigators to be related to MTRX1011A by preferred term in ≥ 2 patients.